Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000259018 is a non-protein-coding natural antisense transcript (NAT) expressed from the strand opposite the EFS gene. NATs are pervasive in mammalian genomes and typically regulate gene expression of their sense partners through a range of mechanisms. These include transcriptional interference (where RNA polymerase activity on opposing strands impedes transcription), RNA masking (where antisense transcripts bind to sense RNA, interfering with splicing or translation), dsRNA-dependent mechanisms like RNA interference, and regulation of chromatin state. NATs tend to be low in abundance, poorly spliced, and often have context-dependent—sometimes tissue- or development-specific—expression and effects. There is no evidence that ENSG00000259018 encodes a protein, serves as a drug target, or plays a recognized direct role in any human disease. Its primary function is presumed to be the post-transcriptional or epigenetic regulation of EFS or nearby genes, as with other natural antisense transcripts.
Not applicable; in the broader sense, NATs may function via mechanisms such as transcriptional interference, RNA masking, double-stranded RNA–dependent processes (including RNA interference or RNA editing), and chromatin remodeling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to EFS (ENSG00000259018).